darlifarnib   Click here for help

GtoPdb Ligand ID: 13803

Synonyms: compound (S)-058 [US20230322711] | KO-2806 | KO2806
Compound class: Synthetic organic
Comment: We have matched the chemical structure for the INN darlifarnib to Kura Oncology's farnesyl transferase inhibitor clinical candidate KO-2806 [1]. The structure is one of those claimed in patent US20230322711A1 [2]. KO-2806 is proposed as an agent for use in combination with RAS inhibitors, to overcome resistance to these drugs. KO-2806 functions to inhibit farnesylation and subsequent activation of mTORC1 [1]. It will also block farnesylation of the CAAX motif on RAS oncogenes that is essential for RAS anchoring to the cell membrane where (proliferative) RAS extracellular signals are transduced [2].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 1
Rotatable bonds 1
Topological polar surface area 110.79
Molecular weight 468.51
XLogP 0.23
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CN1C=NC=C1[C@]2(C3=CC=C(C#N)C(=C3)COC4=CC=CC(=C4)C5=CC(=NC6=C5C=C2C=C6)C#N)N
Isomeric SMILES CN1C=NC=C1[C@]2(C3=CC(=C(C=C3)C#N)COC4=CC=CC(=C4)C5=C6C=C2C=CC6=NC(=C5)C#N)N
InChI InChI=1S/C29H20N6O/c1-35-17-33-15-28(35)29(32)21-6-5-19(13-30)20(9-21)16-36-24-4-2-3-18(10-24)25-12-23(14-31)34-27-8-7-22(29)11-26(25)27/h2-12,15,17H,16,32H2,1H3/t29-/m1/s1
InChI Key GWKGWWBQKOIPNP-GDLZYMKVSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Patel HV, Smith AE, Chan S, Gasendo JG, Samantaray T, Kessler L, Mitra A, Zhu X, Liu YA, Burrows F et al.. (2024)
The farnesyl transferase inhibitor KO-2806 re-sensitizes relapsing tumors to RAS inhibition.
bioRxiv, Preprint. DOI: 10.1101/2024.12.20.629824
2. Zhu X, Ren P, Bai Z, Xiong W, Xu D, Liu YA. (2023)
Macrocyclic compounds and compositions, and methods of preparing and using the same.
Patent number: US20230322711A1. Assignee: Wuxi Apptec Hong Kong Ltd, Kura Oncology Inc. Priority date: 05/06/2023. Publication date: 12/10/2023.